BRKR Stock Recent News

Bruker (BRKR) came out with quarterly earnings of $0.76 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.70 per share a year ago.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2024 financial results before market opening on Thursday, February 13, 2025. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q4 2024 Earnings Webcast” hyperlink in the “Events & Presentat.

Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BRKR's NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.

Bruker Corporation (NASDAQ: BRKR) is undervalued, trading below its fair value of $74, offering significant upside potential due to its strategic acquisitions and improving book value per share. Recent acquisitions enhance BRKR's capabilities in high-growth markets like Life Sciences, Proteomics, and Spatial Biology, driving sustainable revenue growth and positioning the company for future demand. Despite current weaker EPS and operating margins, BRKR's strong R&D investment and successful integration of acquisitions are expected to boost profitability and growth by FY2025.

Bruker launches LUMOS II ILIM QCL-based IR microscope for pharma and life science research.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the launch of the LUMOS™ II ILIM, a quantum cascade laser (QCL) based infrared imaging microscope. The new LUMOS II ILIM redefines performance standards, enabling pharma and life science researchers to capture ultrafast IR images of expansive areas with enhanced spatial resolution. The LUMOS II ILIM features a patented coherence reduction method for infrared laser imaging essentially free from artifacts in both.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 43rd annual J.P. Morgan Healthcare Conference in San Francisco. Frank Laukien, Chairman, President & CEO, Mark Munch, Executive Vice President & President of Bruker Nano Group, and Gerald Herman, Executive Vice President & CFO will present on behalf of the Company on Monday, January 13th, 2025 at 3:45 PM Pacific Standard Time. A live audio webcast of the presentation will.

Biognosys announced its participation in the 23rd Human Proteome Organization (HUPO) World Congress from October 20 to October 24 in Dresden, Germany.

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced the formation of a new division, Bruker Spatial Biology, offering the most diverse and comprehensive solutions for spatial biology. Bruker Spatial Biology brings together in operational coordination three entities: the two businesses of NanoString Technologies and Canopy Biosciences, along with its subsidiary Bruker Spatial Genomics, Inc. (formerly known as Acuity Spatial Genomics, Inc.). Bruker Spatial Biology.